JNJ Johnson & Johnson
- 144.380
- -2.590-1.76%
- 144.510
- +0.130+0.09%
Johnson & Johnson News
J&J to Acquire Skin Disease Treatment Rights From Numab in $1.25 Bln Deal
By Denny Jacob Johnson & Johnson entered into an agreement with Numab Therapeutics to acquire the global rights for bispecific antibody NM26 in an all-cash deal valued at $1.25 billion. The healthca
Express News | NYSE Order Imbalance 766467.0 Shares on Buy Side
Sector Update: Health Care Stocks Retreat Tuesday Afternoon
Health care stocks were declining in Tuesday afternoon trading, with the NYSE Health Care Index falling 1.1% and the Health Care Select Sector SPDR Fund (XLV) down 1.5%. The iShares Biotechnology ETF
Sector Update: Health Care
Health care stocks were retreating Tuesday afternoon, with the NYSE Health Care Index falling 1.1% and the Health Care Select Sector SPDR Fund (XLV) down 1.4%. The iShares Biotechnology ETF (IBB) drop
What the Options Market Tells Us About Johnson & Johnson
Deep-pocketed investors have adopted a bullish approach towards Johnson & Johnson (NYSE:JNJ), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unv
Bio-Thera, Stada Enter Deal for Biosimilar Candidate to Johnson & Johnson's Simponi in EU, UK
Bio-Thera Solutions and Stada Arzneimittel said Tuesday they signed a commercialization and license agreement for BAT2506, a biosimilar candidate to Johnson & Johnson's (JNJ) Simponi that targets tumo
Top Midday Stories: Wall Street Returns to T+1 Settlements; T-Mobile Buys US Cellular's Wireless Ops; Energy Transfer Buys WTG Midstream; GameStop Extends Rally
The Nasdaq Composite was up, the Dow Jones Industrial Average was down, and the S&P 500 was roughly flat in late-morning trading Tuesday as investors returned after an extended holiday weekend. The US
HBM Healthcare Flags NAV Boost From Yellow Jersey-Johnson & Johnson Deal
HBM Healthcare Investments' (HBMN.SW) net asset value per share is set to get a boost from the $1.25 billion sale of its Yellow Jersey Therapeutics portfolio company to Johnson & Johnson (JNJ.F). The
Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion
08:57 AM EDT, 05/28/2024 (MT Newswires) -- Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion Price: 146.91, Change: -0.06, Percent Change: -0.04
Johnson & Johnson (JNJ.US) to buy eczema drug developer Yellow Jersey for $1.25 billion in cash
The Zhitong Finance App learned that Swiss pharmaceutical company Numab Therapeutics announced on Tuesday that Johnson & Johnson (JNJ.US) has agreed to buy its subsidiary Yellow Jersey Therapeutics for US$1.25 billion in cash, including the eczema drug candidate NM26. This bispecific antibody is currently in phase 2 clinical development to treat atopic dermatitis (commonly known as eczema). Under the agreement, Johnson & Johnson will receive the right to develop, manufacture, and commercialize NM26 to treat atopic dermatitis and other targeted conditions. The deal is expected in 2024
Express News | Numab Therapeutics Announces Johnson & Johnson to Acquire Its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to Nm26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
Express News | Johnson & Johnson To Acquire Numab Therapeutics' Subsidiary For Global Rights To NM26 In Atopic Dermatitis For ~$1.25B In Cash
Johnson & Johnson: NM26 Has Potential to Offer Distinctive Benefits Vs. Existing Treatments, Address Key Unmet Needs for AD Patients >JNJ
Johnson & Johnson: NM26 Has Potential to Offer Distinctive Benefits Vs. Existing Treatments, Address Key Unmet Needs for AD Patients >JNJ
Express News | J&J: Enters Agreement With Numab Therapeutics to Acquire Its Wholly Owned Subsidiary for Global Rights to Nm26
Express News | J&J - Proposed Deal for All-Cash Transaction of Approximately $1.25 Bln
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis
Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement with Numab Therapeutics, a clinical-stage biotechnology company advancing a pipeline of immunology and oncology therapeutics, to acquire from Numab's shareholders its wholly-owned subsidiary for the global rights to a novel, investigational first-in-class bispecific antibody, NM26, in an all-cash transaction of approximately $1.25 billion.
Investors Appear Satisfied With Johnson & Johnson's (NYSE:JNJ) Prospects
With a price-to-earnings (or "P/E") ratio of 20.7x Johnson & Johnson (NYSE:JNJ) may be sending bearish signals at the moment, given that almost half of all companies in the United States have P/E rati
3 Top Dividend Stocks to Maximize Your Retirement Income
Johnson & Johnson (JNJ) Stock Falls Amid Market Uptick: What Investors Need to Know
Express News | NYSE Order Imbalance 75741.0 Shares on Buy Side
Analysis
Price Target
No Data
